Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer

Ahmed F. Abdel-Magid

首页> 外文期刊>ACS medicinal chemistry letters >Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer

【24h】

Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer

机译：选择性雌激素受体降解剂（SERDS）：克服ERα-阳性乳腺癌内分泌治疗的抗性的有希望的治疗方法

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《ACS medicinal chemistry letters》 |2017年第11期|共3页
作者
Ahmed F. Abdel-Magid;
展开▼
作者单位

Therachem Research Medilab (India) Pvt. Ltd. Jaipur India;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;化学;
关键词

相似文献

外文文献
中文文献
专利

1. Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer [J] . Ahmed F. Abdel-Magid ACS medicinal chemistry letters . 2017,第11期

机译：选择性雌激素受体降解剂（SERDS）：克服ERα-阳性乳腺癌内分泌治疗的抗性的有希望的治疗方法
2. EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：祖母绿：一个随机的，开放标签，第3阶段试验，以评估享受新的口服选择性雌激素受体降解剂（SERD），VS调查患者对ER + / HER2晚期乳腺癌的内分泌治疗选择的疗效和安全性 CDK4 / 6抑制剂治疗
3. Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：最终分析阶段1对雌激素（RAD1901）的研究，一种新颖的选择性雌激素受体降解剂（SERD），雌激素受体阳性（ER加），人表皮生长因子受体2阴性（HER2-）晚期乳腺癌
4. A Single Tube Screening of Endocrine Therapy Resistance ESR1 Mutations in ER-Positive Breast Cancer [C] . Akihiro Tsuyada, Shunsuke Nakano, Toshimitsu Ichijo, International Molecular Medicine Tri-Conference. . 2016

机译：ER阳性乳腺癌内分泌治疗抗ESR1突变的单管筛选
5. Overcoming Anti-Estrogen Resistance in Estrogen Receptor (ER)-Positive Breast Cancer: Rational Targeting of Phosphatidylinositol 3-Kinase (PI3K) and the Resurrection of Estrogen Therapy [D] . Hosford, Sarah 2018

机译：克服雌激素受体（ER）阳性乳腺癌中的抗雌激素抵抗：磷脂酰肌醇3-激酶（PI3K）的合理靶向和雌激素疗法的复活
6. Selective Estrogen Receptor Degraders (SERDs): A PromisingTreatment to Overcome Resistance to Endocrine Therapy in ERα-PositiveBreast Cancer [O] . Ahmed F. Abdel-Magid, * 2017

机译：选择性雌激素受体降解剂（SERD）：一个有前途的在ERα阳性中克服对内分泌治疗的耐药性的治疗乳腺癌
7. Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer [O] . R. Xiong, Y. Li, J. Zhao, 2019

机译：基本选择性雌激素受体降解剂（B-SERDS）与ER +乳腺癌的新型BET抑制剂组合
8. Type-I Insulin-Like Growth Factor Receptor (IGF1R)-Estrogen Receptor (ER) Crosstalk Contributes to Antiestrogen Therapy Resistance in Breast Cancer Cells. [R] . Fagan, D. 2013

机译：I型胰岛素样生长因子受体（IGF1R） - 雌激素受体（ER）串扰有助于乳腺癌细胞中的抗雌激素治疗抗性。

Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer

著录项

相似文献

相关主题

期刊订阅